A Phase 1 clinical trial for children and adults (ages 12-64 years; 10- and 11-year-old girls may qualify if they are Tanner Stage 3 or higher) with steroid resistance and persistent proteinuria (U Pr/Cr > 1.0) despite therapy is now underway. Estimated GFR must be > 40 ml/min/1.73 M2. This study is sponsored by FibroGen and involves defining the safety and pharmacokinetics of FG-3019, a recombinant human antibody to CTGF.

This study is being conducted at three pediatric nephrology centers in New York, North Carolina and Ohio. Contact John Mahan (john.mahan@nationwidechildrens.org) for additional information.

All study costs are covered for this trial. This is an outpatient trial and subject participation is expected to be approximately 36 weeks. If you know of any eligible and interested patients/families, please contact John Mahan at john.mahan@nationwidechildrens.org.